KIT and acute myeloid leukemia: Interestingly, in the same international consensus, MRD status has been recognized to be a better predictor of relapse risk than the presence of cooperating mutations, such as KIT and FLT3-ITD in CBF AML [1], supporting the essential inclusion of molecular MRD detection into clinical management.